Iontophoretic delivery of carboplatin in a murine model of retinoblastoma

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 3717-3721

  Hayden, Brandy ^a   Jockovich, Maria Elena ^a   Murray, Timothy G ^a   Kralinger, Martina T ^b   Voigt, Monika ^c   Hernandez, Eleut ^a   Feuer, William ^a   Parel, Jean Marie ^a,d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c HUMBOLDT UNIVERSITY   (Germany)

^d University of Miami College of Engineering   (United States)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PLACEBO; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CORNEA DISEASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; HISTOPATHOLOGY; IONTOPHORESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; METHODOLOGY; PATHOLOGY; RETINA TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; IONTOPHORESIS; MICE; MICE, TRANSGENIC; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME;

EID: 33749135711     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0365     Document Type: Article

References (47)

1. Miller RW. Fifty-two forms of childhood cancer: United States mortality experience, 1960-1966. J Pediatr. 1969;75:685-689.
2. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80:263-265.
3. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108:128-132.
4. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11:317-327.
5. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573-579; discussion 579-580.
6. Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001;108:1868-1876.
7. Schipper J, Imhoff SM, Tan KE. Precision megavoltage external beam radiation therapy for retinoblastoma. Front Radiat Ther Oncol. 1997;30:65-80.
8. Monge OR, Flage T, Hatlevoll R, Vermund H. Sightsaving therapy in retinoblastoma: experience with external megavoltage radiotherapy. Acta Ophthalmol (Copenh). 1986;64:414-420.
9. Shields JA, Shields CL, Sivalingam V. Decreasing frequency of enucleation in patients with retinoblastoma. Am J Ophthalmol. 1989;108:185-188.
10. Abramson DH, Ellsworth RM, Tretter P, Adams K, Kitchin FD. Simultaneous bilateral radiation for advanced bilateral retinoblastoma. Arch Ophthalmol. 1981;99:1763-1766.
11. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316-1323.
12. Advani SH, Rao SR, Iyer RS, Pai SK, Kurkure PA, Nair CN. Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma. Med Pediatr Oncol. 1994;22:125-128.
13. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer. 1994;74:722-732.
14. Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol. 1990;74:97-98.
15. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol. 2000;18:2881-2887.
16. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol. 2002;38:411-415.
17. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12-17.
18. Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology. 2001;108:2106-2114; discussion 2114-2115.
19. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118:577-578.
20. Harbour JW, Murray TG, Hamasaki D, et al. Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1996;37:1892-1898.
21. Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118:1549-1554.
22. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
23. O'Brien JM, Marcus DM, Bernards R, et al. A transgenic mouse model for trilateral retinoblastoma. Arch Ophthalmol. 1990;108:1145-1151.
24. Sarraf D, Lee DA. The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol. 1994;10:69-81.
25. Hill JM, Kwon BS, Shimomura Y, Colborn GL, Yaghmai F, Gangarosa LP. Herpes simplex virus recovery in neural tissues after ocular HSV shedding induced by epinephrine iontophoresis to the rabbit cornea. Invest Ophthalmol Vis Sci. 1983;24:243-247.
26. Hill JM, Park NH, Gangarosa LP, et al. Iontophoresis of vidarabine monophosphate into rabbit eyes. Invest Ophthalmol Vis Sci. 1978;17:473-476.
27. Kwon BS, Gangarosa LP, Burch KD, deBack J, Hill JM. Induction of ocular herpes simplex virus shedding by iontophoresis of epinephrine into rabbit cornea. Invest Ophthalmol Vis Sci. 1981;21:442-449.
28. Kwon BS, Gangarosa LP Sr, Green K, Hill JM. Kinetics of ocular herpes simplex virus shedding induced by epinephrine iontophoresis. Invest Ophthalmol Vis Sci. 1982;22:818-821.
29. Barza M, Peckman C, Baum J. Transscleral iontophoresis as an adjunctive treatment for experimental endophthalmitis. Arch Ophthalmol. 1987;105:1418-1420.
30. Behar-Cohen FF, Savoldelli M, Parel JM, et al. Reduction of corneal edema in endotoxin-induced uveitis after application of L-NAME as nitric oxide synthase inhibitor in rats by iontophoresis. Invest Ophthalmol Vis Sci. 1998;39:897-904.
31. Lam TT, Fu J, Chu R, Stojack K, Siew E, Tso MO. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J Ocul Pharmacol. 1994;10:571-575.
32. Lam TT, Fu J, Tso MO. A histopathologic study of retinal lesions inflicted by transscleral iontophoresis. Graefes Arch Clin Exp Ophthalmol. 1991;229:389-394.
33. Behar-Cohen F, El Aouni A, Le Rouic JF, Parel JM, Renard G, Chauvaud D. [Iontophoresis: past and future]. J Fr Ophtalmol. 2001;24:319-327.
34. Kralinger MT, Voigt M, Kieselbach GF, Hamasaki D, Hayden BC, Parel JM. Ocular delivery of acetylsalicylic acid by repetitive coulomb-controlled iontophoresis. Ophthalmic Res. 2003;35:102-110.
35. Voigt M, Kralinger M, Kieselbach G, et al. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci. 2002;43:3299-3306.
36. Behar-Cohen FF, El Aouni A, Gautier S, et al. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res. 2002;74:51-59.
37. Halhal M, Renard G, Courtois Y, BenEzra D, Behar-Cohen F. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004;78:751-757.
38. Yoo SH, Dursun D, Dubovy S, et al. Lontophoresis for the treatment of paecilomyces keratitis. Cornea. 2002;21:131-132.
39. Turner NG, Ferry L, Price M, Cullander C, Guy RH. Iontophoresis of poly-L-lysines: the role of molecular weight? Pharm Res. 1997;14:1322-1331.
40. Bhatia KS, Gao S, Freeman TP, Singh J. Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin. J Pharm Sci. 1997;86:1011-1015.
41. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997;33:161-183.
42. Murray TG, Cicciarelli N, O'Brien JM, et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol. 1997;115:1286-1290.
43. Murray TG, Roth DB, O'Brien JM, et al. Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 1996;114:1385-1389.
44. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116:1209-1212.
45. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947-1950.
46. Karcioglu ZA, Gordon RA, Karcioglu GL. Tumor seeding in ocular fine needle aspiration biopsy. Ophthalmology. 1985;92:1763-1767.
47. Hayden BC, Jockovich ME, Murray TG, et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45:3644-3549.